KBY Biotech Indexv0.0.34
Search
← Pipeline|LUP-4095

LUP-4095

Phase 2/3
By Lupin Limited
Source: Trial-derived·Trials: 2
Modality
Fusion Protein
MOA
CGRPant
Target
Tau
Pathway
Hedgehog
Endometrial Ca
Development Pipeline
Preclinical
~Mar 2015
→ ~Jun 2016
Phase 1
~Sep 2016
→ ~Dec 2017
Phase 2
Mar 2018
→ Jan 2028
Phase 2Current
NCT06168391
706 pts·Endometrial Ca
2019-07→2028-01·Recruiting
NCT07375005
2,548 pts·Endometrial Ca
2018-03→TBD·Terminated
3,254 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-111.8y awayPh3 Readout· Endometrial Ca
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2/3
Termina…
P2/3
Recruit…
Catalysts
Ph3 Readout
2028-01-11 · 1.8y away
Endometrial Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT06168391Phase 2/3Endometrial CaRecruiting706EDSS
NCT07375005Phase 2/3Endometrial CaTerminated2548PANSS
Competitors (10)
DrugCompanyPhaseTargetMOA
TerafutibatinibPfizerPhase 1/2CD38CGRPant
SotovorutinibPfizerApprovedAβCGRPant
ABB-3060AbbViePhase 2LAG-3CGRPant
NVO-9087Novo NordiskPhase 1/2TauCAR-T BCMA
TezecilimabTakedaNDA/BLATauBCL-2i
TAK-8262TakedaNDA/BLATauTNFi
GIL-6239Gilead SciencesPhase 2TNFαCGRPant
TezecilimabRegeneronApprovedIL-23CGRPant
INC-2432IncytePhase 2CD47CGRPant
SematapinarofLegend BiotechNDA/BLAVEGFCGRPant